Fingerprint
Dive into the research topics of 'First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically